Activated STING in a vascular and pulmonary syndrome

New England Journal of Medicine

Volumn 371, Issue 6, 2014, Pages 507-518

  Liu, Y ^a,h   Jesus, A A ^a,h   Marrero, B ^a,h   Yang, D ^c,h   Ramsey, S E ^h,j   Montealegre Sanchez, G A ^a,h   Tenbrock, K ^h,k   Wittkowski, H ^h,l   Jones, O Y ^h,i   Kuehn, H S ^d,h   Lee, C C R ^b,h   DiMattia, M A ^a,h   Cowen, E W ^b,h   Gonzalez, B ^h,m   Palmer, I ^a,h   DiGiovanna, J J ^b,h   Biancotto, A ^c,h   Kim, H ^a,h   Tsai, W L ^a,h   Trier, A M ^a,h   Huang, Y ^a,h   Stone, D L ^e,h   Hill, S ^d,h   Kim, H J ^f,h   St Hilaire, C ^c,h   Gurprasad, S ^d,h   Plass, N ^a,h   Chapelle, D ^a,h   Horkayne Szakaly, I ^h,i   Foell, D ^h,l   Barysenka, A ^h,l   Candotti, F ^e,h   Holland, S M ^g,h   Hughes, J D ^h,n   Mehmet, H ^h,n   Issekutz, A C ^h,j   Raffeld, M ^b,h   McElwee, J ^h,n   Fontana, J R ^c,h   Minniti, C P ^c,h   Moir, S ^g,h   Kastner, D L ^e,h   Gadina, M ^a,h   Steven, A C ^a,h   Wingfield, P T ^a,h   Brooks, S R ^a,h   Rosenzweig, S D ^d,h   Fleisher, T A ^d,h   Deng, Z ^a,h   Boehm, M ^c,h   Paller, A S ^h,o   Goldbach Mansky, R ^a,h   more..

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Department of Laboratory Medicine ^*  (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ WALTER REED ARMY MEDICAL CENTER   (United States)

^j DALHOUSIE UNIVERSITY   (Canada)

^k RWTH AACHEN UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^m HOSPITAL LUIS CALVO MACKENNA   (Chile)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE INHIBITOR; MEMBRANE PROTEIN; STAT1 PROTEIN; STIMULATOR OF INTERFERON GENE PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; GAMMA INTERFERON; IFNG PROTEIN, HUMAN; JANUS KINASE; MPYS PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOINFLAMMATORY DISEASE; CELL ACTIVATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOWN REGULATION; EMBRYO; ENDOTHELIUM CELL; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IFNB1 GENE; INFANT; LUNG DISEASE; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; SIGNAL TRANSDUCTION; STIMULATOR OF INTERFERON GENE ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY; STING GENE; TMEM173 GENE; VASCULAR DISEASE; DNA SEQUENCE; DOMINANT GENE; DRUG ANTAGONISM; FIBROBLAST; GENETICS; INFLAMMATION; METABOLISM; MUTATION; NEWBORN; PEDIGREE; PHOSPHORYLATION; SKIN BLOOD VESSEL DISORDER; SYNDROME; UPREGULATION;

AGE OF ONSET; CYTOKINES; FEMALE; FIBROBLASTS; GENES, DOMINANT; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATION; INTERFERON-GAMMA; JANUS KINASES; LUNG DISEASES; MALE; MEMBRANE PROTEINS; MUTATION; PEDIGREE; PHOSPHORYLATION; SEQUENCE ANALYSIS, DNA; SKIN DISEASES, VASCULAR; STAT1 TRANSCRIPTION FACTOR; SYNDROME; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84905825645     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1312625     Document Type: Article

References (42)

1. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27:621-68.
2. Sanchez GA, de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation. Rheum Dis Clin North Am 2013;39:701-34.
3. Crow YJ. Aicardi-Goutières syndrome. Handb Clin Neurol 2013;113:1629-35.
4. Rice GI, Kasher PR, Forte GM, et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 2012;44:1243-8.
5. Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010;87:866-72.
6. Liu Y, Ramot Y, Torrelo A, et al. Mutations in proteasome subunit β type 8 cause CANDLE syndrome with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2011;64:895-907.
7. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011;1238:91-8.
8. Goldbach-Mansky R. Immunology in clinic review series: focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2012;167:391-404.
9. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM. Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol 2007;82:1353-60. (Pubitemid 350133533)
10. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR. Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol 2010;185:5888-99.
11. Ouyang S, Song X, Wang Y, et al. Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. Immunity 2012;36:1073-86.
12. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012;71:440-7.
13. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014 January 23 (Epub ahead of print).
14. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
15. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 2011;12:959-65. [Erratum, Nat Immunol 2012;13:196.]
16. Keating SE, Baran M, Bowie AG. Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol 2011;32:574-81.
17. Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol 2013;14:19-26.
18. Gall A, Treuting P, Elkon KB, et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012;36:120-31.
19. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A 2012;109:19386-91.
20. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
21. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006;25:373-81. (Pubitemid 44354218)
22. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
23. Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013;339:826-30.
24. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339:786-91.
25. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207:2053-63.
26. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012;36:515-28.
27. Arima K, Kinoshita A, Mishima H, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A 2011;108:14914-9.
28. Kitamura A, Maekawa Y, Uehara H, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest 2011;121:4150-60.
29. Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006;79:731-7. (Pubitemid 44452751)
30. Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007;80:811-5. (Pubitemid 46564418)
31. Beuthien W, Mellinghoff HU, Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005;24:507-15. (Pubitemid 43055044)
32. Szilasiová J, Gdovinová Z, Jautová J, Baloghová J, Ficová M, Bohus P. Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis. Clin Neuropharmacol 2009;32:301-3.
33. Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010;184:3284-97. [Erratum, J Immunol 2010;185:3779.]
34. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
35. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
36. Goodwin JN. Symmetrical peripheral gangrene. Arch Surg 1974;108:780-4.
37. Thornsberry LA, LoSicco KI, English JC III. The skin and hypercoagulable states. J Am Acad Dermatol 2013;69:450-62.
38. Rongioletti F, Ghio L, Ginevri F, et al. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 1999;140:948-51. (Pubitemid 29238474)
39. Graf J. Rheumatic manifestations of cocaine use. Curr Opin Rheumatol 2013;25:50-5.
40. Kondo T, Kobayashi J, Saitoh T, et al. DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A 2013;110:2969-74.
41. Unterholzner L, Keating SE, Baran M, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010;11:997-1004.
42. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008;134:587-98. Skin Diseases